Predictive Oncology ROCE 2024

Predictive Oncology Aktienanalyse

What does Predictive Oncology do?

Predictive Oncology Inc is an emerging company in the field of cancer research and treatment. It was founded in 2002 under the name Precision Therapeutics and has since focused on developing new diagnostic and therapeutic procedures for cancer. The business model of Predictive Oncology is based on collaboration with pharmaceutical companies and research institutions to develop new technologies and products for cancer therapy. The focus is on personalized medicine, which enables treatment options tailored to individual patient needs. The company is divided into several divisions, each covering different areas of cancer research. These include predictive medicine, pharmacy, and diagnostics. Predictive Oncology has developed several products that can be used in predictive medicine. This includes the OncoTect iOCT System, which allows prediction of the effectiveness of chemotherapy for a specific type of cancer. Based on genetic analysis, the system can determine before treatment whether the drug used for chemotherapy is actually effective or if another drug may be more suitable. Another important product of Predictive Oncology is the Skyline Ventures Test Kit, which is used in pharmacy. The kit allows pharmaceutical companies to test the potential effect of a new drug on specific cancer cells before testing it on patients in clinical trials. By pre-testing the effectiveness, unnecessary studies can be avoided and the development of new drugs can be accelerated. In the field of diagnostics, Predictive Oncology has developed the Cchek system, which enables early detection of certain types of cancer through RNA analysis. The system can provide indications of the development of a tumor at an early stage, enabling early treatment. One of the recent developments of Predictive Oncology is the acquisition of Soluble Therapeutics Inc, which specializes in protein analysis. Through the acquisition, Predictive Oncology hopes to further increase its capacities in personalized cancer treatment. Overall, Predictive Oncology is one of the leading companies in the field of cancer research. Through a consistent focus on personalized medicine and close collaboration with research institutions and pharmaceutical companies, the company has already produced some promising developments. In the future, it is expected that Predictive Oncology will bring further innovative products and technologies to the market to treat cancer patients more effectively. Predictive Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Predictive Oncology's Return on Capital Employed (ROCE)

Predictive Oncology's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Predictive Oncology's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Predictive Oncology's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Predictive Oncology’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Predictive Oncology stock

What is the ROCE (Return on Capital Employed) of Predictive Oncology this year?

The ROCE of Predictive Oncology is -1.68 undefined this year.

How has the ROCE (Return on Capital Employed) of Predictive Oncology developed compared to the previous year?

The ROCE of Predictive Oncology has increased by 139.99% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Predictive Oncology?

A high Return on Capital Employed (ROCE) indicates that Predictive Oncology has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Predictive Oncology?

A low ROCE (Return on Capital Employed) can indicate that Predictive Oncology has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Predictive Oncology impact the company?

An increase in the ROCE of Predictive Oncology can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Predictive Oncology affect the company?

A decrease in ROCE of Predictive Oncology can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Predictive Oncology?

Some factors that can affect Predictive Oncology's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Predictive Oncology so important for investors?

The ROCE of Predictive Oncology is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Predictive Oncology take to improve the ROCE?

To improve the ROCE, Predictive Oncology can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Predictive Oncology pay?

Over the past 12 months, Predictive Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Predictive Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Predictive Oncology?

The current dividend yield of Predictive Oncology is .

When does Predictive Oncology pay dividends?

Predictive Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Predictive Oncology?

Predictive Oncology paid dividends every year for the past 0 years.

What is the dividend of Predictive Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Predictive Oncology located?

Predictive Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Predictive Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Predictive Oncology from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Predictive Oncology pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Predictive Oncology in the year 2023?

In the year 2023, Predictive Oncology distributed 0 USD as dividends.

In which currency does Predictive Oncology pay out the dividend?

The dividends of Predictive Oncology are distributed in USD.